SU5408 - CAS:15966-93-5 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	SU5408 促销
英文名称:	SU5408
别名:	VEGFR2 Kinase Inhibitor I
CAS No:	15966-93-5	分子式:	C₁₈H₁₈N₂O₃	分子量:	310.4
CAS No:	15966-93-5
分子式:	C₁₈H₁₈N₂O₃
分子量:	310.4

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

S10047 SU5408 ≥98% (psaitong)

相关产品

包装规格：

5mg 25mg 50mg 100mg in glass bottle

溶解性：

溶于DMSO( 6mg/mL)和乙醇

产品描述：

基本信息

产品编号：S10047
产品名称：SU5408
CAS:	15966-93-5	储存条件	粉末	-20℃	四年
分子式：	C18H18N2O3		溶于液体	-80℃	两年
分子量	310.40			-20℃	一个月
化学名：	1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester
Solubility (25°C)	体外	DMSO	6mg/mL (19.33mM)
		Ethanol	Insoluble
		Water	Insoluble
	体内	现配现用
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	3.2222mL	16.1108mL	32.2217mL
5mM	0.6444mL	3.2222mL	6.4443mL
10mM	0.3222mL	1.6111mL	3.2222mL

生物活性

产品描述

一种高度选择性和细胞可渗透的酪氨酸激酶（RTK）抑制剂，IC50：70nM。

靶点/IC₅₀

VEGFR2
(Cell-free assay)

70nM

体外研究

3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 (VEGFR2 Kinase Inhibitor I) is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 (VEGFR2 Kinase Inhibitor I) shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50>100 µM)

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

SU5408 have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. SU5408 is found to be the most potent and selective VEGFR2 inhibitor among the compounds. SU5408 shows little or no effect against receptors for platelet-derived growth factor, epidermal growth factor, or insulin-like growth factor (IC50>100 μM).

在体内：
请根据您的实验动物和给药方式选择适当的溶解方案，配制前请先配制澄清的储备液，再依次添加助溶剂 (为保证实验结果的可靠性，体内实验的工作液，建议您现用现配，当天使用；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分比是指该溶剂在您配制终溶液中的体积占比)：
1. 请依序添加每种溶剂:10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility:0.77mg/mL(2.48mM); Suspende solution; Need ultrasonic
2.请依序添加每种溶剂:10% DMSO 90% corn oil
Solubility: ≥0.77mg/mL (2.48mM); Clear solution。
以上方法仅供参考

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献